Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

"Undruggable KRAS": druggable after all.

Genes & development - 7 Jan 2025

Cox Adrienne D, Der Channing J

Abstract excerpt

The three RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene family in cancer. KRAS is the predominant isoform mutated in cancer and is most prevalently mutated in major causes of cancer deaths including lung, colorectal, and pancreatic cancers. Despite extensive academic and industry efforts to target KRAS, it would take nearly four decades before approval of the first clinically...

Topics

Humans
Proto-Oncogene Proteins p21(ras)
Mutation
Neoplasms
Animals
Antineoplastic Agents
Drug Resistance, Neoplasm
Molecular Targeted Therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39638567
DOI: 10.1101/gad.352081.124
PMCID: PMC11789494

Genes

KRAS
HRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

"Undruggable KRAS": druggable after all.PMID 39638567Read ↗

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Semantic proximity Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read ↗

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.Semantic proximity Read ↗

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.Semantic proximity Read ↗

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.Semantic proximity Read ↗

KRAS: From undruggable to a druggable Cancer Target.Semantic proximity Read ↗

Stopping the beating heart of cancer: KRAS reviewed.Semantic proximity Read ↗

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.